| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| prazosin hydrochloride | Tablet, uncoated | 5.476 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 9/02/2026 |
| omeprazole | Capsule, enteric | 20 mg | Current | Limited Availability | Manufacturing | 9/02/2026 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 13.88 mg~86.751 mg | Current | Limited Availability | Manufacturing | 9/02/2026 |
| cabergoline | Tablet, uncoated | 1 mg | Anticipated | Available | Manufacturing | 9/02/2026 |
| atovaquone~proguanil hydrochloride | Tablet, film coated | 62.5 mg~25 mg | Resolved | Available | Unexpected increase in consumer demand | 9/02/2026 |
| salbutamol sulfate | Inhalation | 2.4 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 6/02/2026 |
| paclitaxel | Injection, powder for | 100 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 6/02/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 555 mg | Resolved | Available | Manufacturing | 6/02/2026 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Current | Unavailable | Manufacturing | 6/02/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Limited Availability | Manufacturing | 6/02/2026 |
| olanzapine | Tablet, orally disintegrating | 10 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/02/2026 |
| enalapril maleate | Tablet | 5 mg | Resolved | Available | Manufacturing | 6/02/2026 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Resolved | Available | Manufacturing | 6/02/2026 |
| clindamycin hydrochloride | Capsule, hard | 162.87 mg | Current | Limited Availability | Manufacturing | 6/02/2026 |
| clindamycin hydrochloride | Capsule, hard | 162.87 mg | Anticipated | Available | Manufacturing | 6/02/2026 |
| levetiracetam | Injection, intravenous infusion | 100 mg/mL | Anticipated | Available | Manufacturing | 6/02/2026 |
| ethinylestradiol~levonorgestrel | Tablet, uncoated | 30 microgram~150 microgram | Anticipated | Available | Manufacturing | 6/02/2026 |
| citalopram hydrobromide | Tablet, film coated | 12.495 mg | Resolved | Available | Manufacturing | 6/02/2026 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 6/02/2026 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 6/02/2026 |
| hydrochlorothiazide~olmesartan medoxomil | Tablet | 12.5 mg~40 mg | Resolved | Available | Manufacturing | 6/02/2026 |
| eplerenone | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 6/02/2026 |
| timolol maleate~latanoprost | Eye Drops, solution | 6.83 mg/mL~.05 mg/mL | Current | Unavailable | Manufacturing | 6/02/2026 |
| midodrine hydrochloride | Tablet | 2.5 mg | Current | Unavailable | Manufacturing | 6/02/2026 |
| paclitaxel | Injection, powder for | 100 mg | Current | Limited Availability | Manufacturing | 6/02/2026 |
| lamotrigine | Tablet, chewable | 200 mg | Current | Unavailable | Manufacturing | 6/02/2026 |
| anastrozole | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 6/02/2026 |
| clindamycin phosphate | Cream | 22.8 mg/g | Anticipated | Available | Unexpected increase in consumer demand | 6/02/2026 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 6/02/2026 |
| vinorelbine tartrate | Capsule, soft | 27.7 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/02/2026 |
| vinorelbine tartrate | Capsule, soft | 41.55 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/02/2026 |
| ceftazidime pentahydrate | Injection, powder for | 1.164 g | Anticipated | Available | Unexpected increase in consumer demand | 5/02/2026 |
| varenicline tartrate~varenicline tartrate | Tablet, film coated | .86 mg~1.71 mg | Anticipated | Available | Manufacturing | 5/02/2026 |
| nimodipine | Tablet, film coated | 30 mg | Current | Limited Availability | Manufacturing | 5/02/2026 |
| formoterol fumarate | Inhalation, powder for | 12 microgram | Current | Limited Availability | Manufacturing | 5/02/2026 |
| glimepiride | Tablet, uncoated | 1 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| glimepiride | Tablet, uncoated | 2 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| clindamycin phosphate | Injection, solution | 0 QS | Current | Limited Availability | Manufacturing | 4/02/2026 |
| bromocriptine mesilate | Tablet, uncoated | 2.87 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| isoniazid | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 4/02/2026 |
| olanzapine | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| amisulpride | Tablet | 200 mg | Anticipated | Available | Manufacturing | 4/02/2026 |
| galantamine hydrobromide | Capsule, modified release | 30.768 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 4/02/2026 |
| lamivudine | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 4/02/2026 |
| clevidipine | Injection, emulsion | 25 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 4/02/2026 |
| gabapentin | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| fenofibrate | Tablet | 48 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| rosuvastatin calcium | Tablet, film coated | 41.68 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| rosuvastatin calcium | Tablet, film coated | 10.42 mg | Resolved | Available | Manufacturing | 4/02/2026 |
| pregabalin | Capsule, hard | 150 mg | Current | Unavailable | Unexpected increase in consumer demand | 4/02/2026 |
| pregabalin | Capsule, hard | 75 mg | Resolved | Available | Manufacturing | 4/02/2026 |
| pregabalin | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 4/02/2026 |
| atomoxetine hydrochloride | Capsule, hard | 20.57 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| bazedoxifene acetate~conjugated estrogens | Tablet, modified release | 22.56 mg~.45 mg | Current | Unavailable | Commercial Changes / Commercial viability | 4/02/2026 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| erenumab | Injection, solution | 70 mg | Resolved | Available | Unexpected increase in consumer demand | 4/02/2026 |
| dabigatran etexilate mesilate | Capsule, hard | 126.83 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| posaconazole | Tablet, modified release | 100 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| iopromide | Injection, solution | 768.86 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 4/02/2026 |
| progesterone | Pessary | 400 mg | Current | Emergency Supply Only | Transport / Logistic issues / Storage capacity issues | 4/02/2026 |
| metoprolol succinate | Tablet, modified release | 23.75 mg | Current | Unavailable | Unexpected increase in consumer demand | 4/02/2026 |
| methotrexate | Tablet | 2.5 mg | Anticipated | Available | Manufacturing | 4/02/2026 |
| sumatriptan succinate | Tablet, film coated | 69.99 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| naproxen | Tablet | 500 mg | Anticipated | Available | Manufacturing | 4/02/2026 |
| aripiprazole monohydrate | Injection, powder for | 416.07 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| olanzapine | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 4/02/2026 |
| ethinylestradiol~norethisterone | Tablet, uncoated | 36 microgram~500 microgram | Current | Limited Availability | Manufacturing | 4/02/2026 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Anticipated | Available | Manufacturing | 4/02/2026 |
| olanzapine | Wafer | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 4/02/2026 |
| ampicillin | Injection, powder for | 500 mg | Anticipated | Available | Unexpected increase in consumer demand | 4/02/2026 |
| lamotrigine | Tablet, dispersible | 100 mg | Current | Unavailable | Manufacturing | 4/02/2026 |
| gabapentin | Capsule, hard | 400 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| imipramine hydrochloride | Tablet, sugar coated | 10 mg | Anticipated | Available | Manufacturing | 3/02/2026 |
| bupivacaine hydrochloride | Injection, solution | 5 mg/mL | Resolved | Available | Manufacturing | 3/02/2026 |
| adenosine | Injection, solution | 6 mg | Anticipated | Available | Manufacturing | 3/02/2026 |
| galantamine hydrobromide | Capsule, modified release | 10.256 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2026 |
| letrozole | Tablet, film coated | 2.5 mg | Resolved | Available | Manufacturing | 3/02/2026 |
| Somatropin | Injection, powder for | 5 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 3/02/2026 |
| lamivudine | Tablet, film coated | 300 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| rocuronium bromide | Injection, solution | 50 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| temozolomide | Capsule, hard | 140 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 160 mg~12.5 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Anticipated | Available | Manufacturing | 3/02/2026 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| linezolid | Tablet, film coated | 600 mg | Resolved | Available | Manufacturing | 3/02/2026 |
| crisaborole | Ointment | 2 % w/w | Anticipated | Available | Unexpected increase in consumer demand | 3/02/2026 |
| doxepin hydrochloride | Capsule, hard | 11.3 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| deferasirox | Tablet, film coated | 90 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| deferasirox | Tablet, film coated | 360 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| escitalopram oxalate | Tablet, film coated | 25.548 mg | Resolved | Available | Manufacturing | 3/02/2026 |
| enoxaparin sodium | Injection, solution | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 3/02/2026 |
| rimegepant sulfate | Tablet, orally disintegrating | 85.65 mg | Resolved | Available | Manufacturing | 3/02/2026 |
| daunorubicin hydrochloride | Injection, powder for | 20 mg | Anticipated | Available | Manufacturing | 3/02/2026 |
| tamoxifen citrate | Tablet, uncoated | 15.2 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| tamoxifen citrate | Tablet, uncoated | 30.4 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| vancomycin hydrochloride | Injection, powder for | 1000 mg | Anticipated | Available | Manufacturing | 3/02/2026 |
| gramicidin~framycetin sulfate~dexamethasone | Ear Drops | .05 mg/mL~5 mg/mL~.5 mg/mL | Current | Limited Availability | Manufacturing | 3/02/2026 |
| levodopa~carbidopa monohydrate | Tablet, uncoated | 100 mg~26.9 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| parecoxib sodium | Injection, powder for | 42.36 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 3/02/2026 |
| lamotrigine | Tablet, dispersible | 200 mg | Current | Unavailable | Manufacturing | 3/02/2026 |
| oxycodone hydrochloride | Tablet, uncoated | 5 mg | Current | Limited Availability | Manufacturing | 2/02/2026 |
| phenylephrine hydrochloride~prednisolone acetate | Eye Drops, suspension | 1.2 mg/mL~10 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 2/02/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 2/02/2026 |
| ibuprofen | Injection, solution | 5 mg/mL | Current | Unavailable | Unexpected increase in consumer demand | 2/02/2026 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 2/02/2026 |
| oseltamivir phosphate | Capsule, hard | 98.5 mg | Resolved | Available | Unexpected increase in consumer demand | 2/02/2026 |
| gliclazide | Tablet, uncoated | 80 mg | Anticipated | Available | Manufacturing | 2/02/2026 |
| escitalopram oxalate | Tablet, film coated | 12.774 mg | Anticipated | Available | Manufacturing | 2/02/2026 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 4.986 mg | Resolved | Available | Manufacturing | 2/02/2026 |
| lamotrigine | Tablet | 100 mg | Current | Unavailable | Manufacturing | 2/02/2026 |
| labetalol hydrochloride | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 2/02/2026 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Manufacturing | 2/02/2026 |
| simvastatin | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 2/02/2026 |
2026年2月9日